Michael Hughes

ORCID: 0000-0003-1493-486X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • Breast Lesions and Carcinomas
  • Cutaneous Melanoma Detection and Management
  • HER2/EGFR in Cancer Research
  • Urological Disorders and Treatments
  • Breast Implant and Reconstruction
  • Venous Thromboembolism Diagnosis and Management
  • Lymphatic System and Diseases
  • Genital Health and Disease
  • Abdominal Trauma and Injuries
  • Cancer Genomics and Diagnostics
  • Atrial Fibrillation Management and Outcomes
  • Sarcoma Diagnosis and Treatment
  • Trauma and Emergency Care Studies
  • Vascular Tumors and Angiosarcomas
  • Vascular anomalies and interventions
  • Cardiac Arrhythmias and Treatments
  • Urologic and reproductive health conditions
  • Cancer and Skin Lesions
  • Cancer Treatment and Pharmacology
  • Melanoma and MAPK Pathways
  • Pelvic and Acetabular Injuries
  • LGBTQ Health, Identity, and Policy
  • Infrared Thermography in Medicine
  • Trauma Management and Diagnosis

Australian National University
2021-2025

Sydney Adventist Hospital
2014-2025

University of Manchester
2024

Charing Cross Hospital
2024

Manchester Academic Health Science Centre
2024

Northern Sydney Local Health District
2022-2023

Queen's University Belfast
2022

The University of Sydney
1999-2021

Cancer Council Australia
2021

Melanoma Institute Australia
2011-2021

To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma correlate status with clinicopathologic features outcome.Consecutive BRAF-tested Australian patients (n = 197) were observed prospectively. A comprehensive range variables correlated mutation status, a survival analysis was conducted.Forty-eight percent had mutation; 70 (74%) V600E, 19 (20%) V600K, six (6%) other genotypes. Other than age at diagnosis distant metastasis (median age, 56 v 63 years for...

10.1200/jco.2010.32.4327 article EN Journal of Clinical Oncology 2011-02-23

Background: This study compared rates of progression to chronic breast cancer-related lymphedema (defined as ≥ 10% arm volume change from baseline requiring complex decongestive physiotherapy [CDP]) following an intervention for subclinical (S-BCRL) triggered by bioimpedance spectroscopy (BIS) or tape measurement (TM). Methods and Results: stratified, randomized, international trial enrolled new cancer patients undergoing: mastectomy/partial mastectomy, axillary treatment (dissection,...

10.1089/lrb.2021.0084 article EN cc-by Lymphatic Research and Biology 2022-01-31

Merkel cell carcinoma is an aggressive primary cutaneous neuroendocrine carcinoma. Patients remain at high risk of locoregional and distant relapse despite treatment. Most studies support the incorporation adjuvant radiotherapy in reducing relapse.Between 1980 2002, 86 patients diagnosed with were treated curative intent Westmead Hospital, Sydney. Multivariate analysis was performed using Cox regression analysis. Disease-free survival overall calculated Kaplan-Meier curves.Median age...

10.1111/j.1445-2197.2005.03353.x article EN ANZ Journal of Surgery 2005-05-01

Electroporation therapy (EPT) is a novel treatment modality that uses brief, high-intensity, pulsed electrical currents to enhance the uptake of chemotherapeutic agents, vaccines and genes into cells. This technique potentially useful for patients with secondary and, possibly, some primary tumours. Nineteen metastatic melanoma were enrolled in phase two, randomized, open-label study comparing intralesional bleomycin+EPT bleomycin alone. Of 18 lesions, 13 (72%) showed complete response, one...

10.1097/00008390-200502000-00008 article EN Melanoma Research 2005-02-01

Background To evaluate risk factors (treatment‐related, comorbidities, and lifestyle) for breast cancer–related lymphedema (BCRL) within the context of a Prospective Surveillance Early Intervention (PSEI) model care subclinical BCRL. Methods The parent randomized clinical trial assigned patients newly diagnosed with cancer to PSEI either bioimpedance spectroscopy (BIS) or tape measurement (TM). Surgical, systemic radiation treatments, lifestyle were recorded. Detection BCRL (change from...

10.1002/cncr.34377 article EN Cancer 2022-07-07

Abstract Background The appropriate management of melanoma metastatic to inguinal lymph nodes remains controversial. aim this study was identify disease- and treatment-related factors that influence the outcome patients undergoing therapeutic groin dissection for clinically detectable node metastases. Methods A retrospective analysis performed on data collected from case records who had a between 1984 1998. Results Some 132 were suitable inclusion. Sixty superficial (SLND) 72 combined pelvic...

10.1046/j.1365-2168.2000.01439.x article EN British journal of surgery 2000-07-01

In Brief Background: Accurate reporting of prognostically important histopathologic parameters is critical for optimal management melanoma patients. Previous studies have shown that assessment Breslow thickness and ulceration more reproducible between pathologists than estimation Clark level. However, detailed quantification the magnitude variation observers its effect on staging has not been reported. Methods: Nine hundred twelve patients referred to Sydney Melanoma Unit (SMU) with...

10.1097/sla.0b013e31819ed973 article EN Annals of Surgery 2009-04-01

Abstract Background The clinical management of the axilla in early breast cancer has changed since Z0011 trial, which showed that axillary lymph node dissection (ALND) is not necessary select patients with a positive sentinel biopsy (SLNB). Studies have shown significant decrease rates completion ALND (cALND) Z0011. aims this study were to investigate effect trial on nodes and trends surgical 2005 Australia New Zealand. Methods This utilized prospectively maintained data from BreastSurgANZ...

10.1111/ans.19404 article EN cc-by-nc-nd ANZ Journal of Surgery 2025-01-28

The molecular chaperone Heat shock protein 90 (Hsp90) is essential for the folding, stability, and activity of several drivers oncogenesis. Hsp90 inhibitors are currently under clinical evaluation cancer treatment, however their efficacy limited by lack biomarkers to optimize patient selection. We have recently identified tumor suppressor tuberous sclerosis complex 1 (Tsc1) as a new co-chaperone that affects binding its inhibitors. Highly variable mutations TSC1 been previously in bladder...

10.18632/oncotarget.27217 article EN Oncotarget 2019-10-08
Coming Soon ...